IL Receptor
Interleukin receptors (IL receptors) are a group of receptors that bind to interleukins, a family of cytokines that play essential roles in immune system regulation, inflammation, and hematopoiesis. Dysregulation of interleukin signaling is associated with various inflammatory and autoimmune diseases, making IL receptors critical targets for therapeutic intervention. IL receptor antagonists are being explored for the treatment of conditions such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. At CymitQuimica, we offer a range of high-quality IL receptor modulators to support your research in cytokine signaling, immunology, and inflammatory disease therapy.
Found 124 products for "IL Receptor".
Filter by
Purity percentage
0
100
|
0
|
50
|
90
|
95
|
100
- Lower prices
- Higher prices
- Lower purities
- Higher purities
- Faster estimated delivery
Briakinumab
CAS:Briakinumab (ABT-874) is a monoclonal antibody targeting IL-12, used in the research of psoriasis multiple sclerosis.Purity:>95%Color and Shape:Transparent LiquidMolecular weight:143.86 kDa (Predicted)Dupilumab
CAS:Dupilumab (REGN-668) is a systemic immunomodulator for AD.Purity:95.00% - >99.2%Color and Shape:White LiquidMolecular weight:149.8 kDa (Predicted)Risankizumab
CAS:Risankizumab (BI 655066) is a monoclonal antibody for psoriasis, targeting IL-23, with high affinity (Kd <10 pM) and an IC50 of 2 pM.Purity:SDS-PAGE:95.3%;SEC-HPLC:98.3%Color and Shape:Transparent LiquidMolecular weight:145.85 kDa (Predicted)Olamkicept
CAS:Olamkicept (FE-301) is a soluble gp130-Fc-fusion protein that inhibits interleukin 6 (IL-6) trans signaling.Purity:98.2% (SDS-PAGE); 98.8% (SEC-HPLC) - 99.3% (SDS-PAGE); 97.6% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:93.14 kDa (Predicted)Mirikizumab
CAS:Mirikizumab (LY3074828) is a humanized antibody targeting the p19 subunit of interleukin-23 (IL-23).Purity:98.41% (SEC-HPLC) - 98.41% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:144.26 kDa (Predicted)Perakizumab
CAS:Perakizumab (RG4934) is a humanized monoclonal antibody targeting IL-17A, used in the study of psoriatic arthritis and other autoimmune diseases.Purity:95.28% (SEC-HPLC) - 99.66% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.8 kDa (Predicted)Brodalumab
CAS:Brodalumab (AMG 827), a human IgG2 monoclonal antibody, inhibits IL-17R, treating psoriasis.Purity:98.3%Color and Shape:Transparent LiquidMolecular weight:144.06 kDa (Predicted)Ordesekimab
CAS:Ordesekimab (AMG 714) is a human anti-IL-15 IgG1 κ monoclonal antibody for studying NRCD.Purity:> 95%Color and Shape:Transparent LiquidMolecular weight:145.12 kDa (Predicted)Siltuximab
CAS:Siltuximab（CNTO-328） is a monoclonal antibody with anti-tumor activity targeting IL-6 for the study of giant lymph node hyperplasia (MCD) and COVID-19.Purity:100% (SEC-HPLC) - >95% (SDS-PAGE); 100% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:144.98 kDa (Predicted)Sarilumab
CAS:Sarilumab: Potent IL-6 blocker, human antibody, reduces inflammation, treats rheumatoid arthritis.Purity:97.4%Color and Shape:Transparent LiquidMolecular weight:144.12 kDa (Predicted)Levilimab
CAS:Levilimab (BCD-089) is a fully humanized human monoclonal antibody targeting membrane-bound and soluble IL-6 R for the study of rheumatoid arthritis.Purity:97.8% (SDS-PAGE); 97.3% (SEC-HPLC) - 97.8% (SDS-PAGE); 97.3% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.69 kDa (Predicted)Imsidolimab
CAS:Imsidolimab (ANB 019) is a humanized anti-IL-36R monoclonal antibody that inhibits IL-36 signaling and can be used to study systemic pustular psoriasis.Purity:99.1% (SDS-PAGE); 96.7% (SEC-HPLC) - 99.1% (SDS-PAGE); 96.7% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:146.71 kDa (Predicted)Nidanilimab
CAS:Nidanilimab (CAN04) is an IL1RAP antibody with 1.10 pM affinity and antitumor effects on NSCLC and PDAC.Purity:> 95%Color and Shape:Transparent LiquidMolecular weight:~150 kDaOlokizumab
CAS:Revdofilimab (ABBV-368) is a human IgG monoclonal antibody targeting OX 40 with potential anticancer activity.Purity:99% (SDS-PAGE); 98.3% (SEC-HPLC) - 99% (SDS-PAGE); 98.3% (SEC-HPLC)Color and Shape:Transparent LiquidMolecular weight:145.39 kDa (Predicted)Spesolimab
CAS:Spesolimab (BI 655130) is an antibody targeting IL-36 receptor, key in immunity, for systemic pustular psoriasis and dermatitis studies.Purity:> 95%Color and Shape:Transparent LiquidMolecular weight:~150 kDa2-Benzothiazolamine
CAS:2-ABT: nitrogen-rich heterocycle used in drug synthesis, inhibits P450, with anti-inflammatory, anticonvulsant, anticancer properties.Formula:C7H6N2SPurity:99.09% - 99.3%Color and Shape:SolidMolecular weight:150.201IL-15-IN-1
CAS:IL-15-IN-1 is a selective and potent Interleukin 15 (IL-15) inhibitor, inhibiting the proliferation of IL-15-dependent cells (IC50: 0.8 μM).Formula:C30H36N6O4SPurity:99.16%Color and Shape:SolidMolecular weight:576.71Enokizumab
CAS:Enokizumab (MEDI-528) is a monoclonal antibody against interleukin IL-9. Enokizumab can be used to study asthma.Purity:SDS-PAGE:95% SEC-HPLC:99.23%Color and Shape:Transparent LiquidMolecular weight:145.98 kDa (Predicted)Tildrakizumab
CAS:Tildrakizumab (SCH 900222) is a humanized antibody against IL-23, with a 136 pM Kd, used for psoriasis research.Purity:> 95%Color and Shape:Transparent LiquidMolecular weight:144.44 kDa (Predicted)Elsilimomab
CAS:Elsilimomab (B-E8) is a monoclonal antibody targeting IL-6, inhibiting the induction of bone marrow stromal cell senescence by dnmt3a mutation clones.Purity:>95%Color and Shape:Transparent LiquidMolecular weight:145.96 kDa (Predicted)
